Immunohistology of Epstein-Barr Virus-Associated Antigens in B Cell Disorders From Immunocompromised Individuals

Thomas, J A; Hotchin, Neil A.; Allday, Martin J.; Amlot, Peter; Rose, Marlene L.; Yacoub, Magdi H.; Crawford, Darrell H. G.

doi:10.1097/00007890-199005000-00022

Cited by 184 publications

(101 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sections were then incubated with appropriately diluted primary antibodies: monoclonal antibodies CS1 to 4, specific for the EBVencoded LMP-1 and immune human sera containing activity to EBNA-1 (Dako). 15,16 The expression of Ki67 antigen was immunohistochemically determined on paraffin-embedded tissue sections (Dako). 17 …”

Section: Methodsmentioning

confidence: 99%

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

et al. 1999

Self Cite

View full text Add to dashboard Cite

Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized complication of organ transplantation. The aim of this study, performed over 9 years, was to examine the histopathological findings, clinical course, and outcome of patients who, having undergone orthotopic liver transplantation (OLT), developed PTLD. The sample included 7 adult liver allograft recipients (1.7%), 4 men and 3 women, with a mean age of 53 years (range, 40 to 61 years) who developed PTLD 1 to 36 months post-OLT (mean, 6 months). Four patients received either antithymocyte globulin as primary immunosuppression or OKT3 for steroidresistant cellular rejection. Four patients had localized hepatic tumor with or without regional lymph node involvement, 2 patients had extralymphoreticular disease (head of pancreas and chest wall), and 1 patient had spleen and lymph node involvement. All tumors were B-cell lymphomas; three polymorphic and four monomorphic. Clonality was assessed by immunostaining for kappa and lambda and gene rearrangement. Monoclonality was found in 4 patients and polyclonality in 2 (1 of whom progressed to monoclonality); in 2 patients, clonality could not be determined. Immunohistochemistry findings for the presence of the Epstein-Barr virus (EBV)-determined nuclear antigen and the latent membrane protein 1 were noted in lymphoma tissue in 6 patients. Immunosuppressive therapy was decreased in all patients. Polyclonal tumors were treated with acyclovir (1 patient is in complete remission and 1 patient died), and monoclonal tumors with systemic chemotherapy (2 patients are in complete remission and 2 patients died). One patient was treated with monoclonal antibodies (CD20) but failed to respond, and 1 patient was treated with excision and is in complete remission. The mortality rate was 43%; for the remainder, median survival is 21 months (range, 10 to 42 months). We conclude that PTLD may re-present early after OLT. EBV has a special role in the pathogenesis, combined with immunosuppressive therapy. The outcome is poor, and new therapeutic approaches are needed.

show abstract

Section: Methodsmentioning

confidence: 99%

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

et al. 1999

Self Cite

View full text Add to dashboard Cite

show abstract

“…The expression of all latent genes is commonly called 'growth program' or 'latency III program' (Rowe et al, 1992). This program seems to be the one most frequently expressed in vivo during the acute phase of infectious mononucleosis or in immunodeficient patients (Thomas et al, 1990;Hopwood et al, 2002;Dolcetti and Masucci, 2003). Other phases of the EBV cycle are associated with more restricted patterns of viral gene expression, as are most of the EBV-related tumors: BL cells express only Epstein-Barr virus nuclear antigen 1 (EBNA1) (latency I) , whereas EBV-positive Hodgkin's lymphoma usually expresses EBNA1, latent membrane proteins 1 and 2 (LMP1 and LMP2) (latency II) (Pallesen et al, 1991;Young et al, 1991).…”

Section: Introductionmentioning

confidence: 99%

Chromosomal rearrangements after ex vivo Epstein–Barr virus (EBV) infection of human B cells

et al. 2009

View full text Add to dashboard Cite

The Epstein-Barr virus (EBV) is carried by more than 90% of the adult world population and has been implicated in several human malignancies. Its ability to induce unlimited in vitro proliferation of B cells is frequently used to generate lymphoblastoid cell lines (LCLs). In this study, we have investigated the evolution of two LCLs up to 25 weeks after EBV infection. LCLs were karyotyped once a month by spectral karyotyping (SKY). LCLs but not mitogen-activated B cells showed evidence of DNA damage and DNA damage response within the first 2 weeks. After 4 weeks, the former, but not the latter, showed a high level of non-clonal structural aberrations, mainly deletions, fragments, dicentric chromosomes and unbalanced translocations. Genomic instability decreased thereafter over time. Nonrandom aneuploidy 12 weeks after infection showed clonal evolution in culture. After 25 weeks post-infection, most cells exhibited karyotypic stability. Chromosomal aberrations were compatible with telomere dysfunction, although in the absence of telomere shortening. The telomere capping protein TRF2 was partially displaced from telomeres in EBV-infected cells, suggesting an EBVmediated uncapping problem. In conclusion, this study suggests that DNA damage and telomere dysfunction contribute to EBV-related chromosomal instability in early LCLs.

show abstract

“…7 EBV infection such as acquired immunodeficiency syndrome in immunocompromised patients or allograft recipients receiving immunosuppressive therapy evoke polyclonal B cell proliferative disorders, frequently resulting in monoclonal malignant lymphomas. 8,9 These lymphomas are most often diffuse lymphomas of B cell type and exhibit EBV DNA. 8,9 The clonality of B cell lymphoma is determined primarily by the rearrangement pattern of immunoglobulin (Ig) genes and sometimes by that of some oncogenes.…”

Section: Introductionmentioning

confidence: 99%

Appearance of a different clone of Epstein–Barr virus genome in recurrent tumor of pyothorax-associated lymphoma (PAL) and a mini-review of PAL

et al. 1998

View full text Add to dashboard Cite

Immunohistology of Epstein-Barr Virus-Associated Antigens in B Cell Disorders From Immunocompromised Individuals

Cited by 184 publications

References 0 publications

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

Chromosomal rearrangements after ex vivo Epstein–Barr virus (EBV) infection of human B cells

Appearance of a different clone of Epstein–Barr virus genome in recurrent tumor of pyothorax-associated lymphoma (PAL) and a mini-review of PAL

Contact Info

Product

Resources

About